Table 5

Effect of EGML or GCE on plasma lipids and atherogenic biomarkers in overweight subjects

Groups

Placebo

GCE

EGML

Before

After

Before

After

Before

After

HTR (%)

21.36 ± 1.56

22.49 ± 1.94

21.08 ± 1.48

23.14 ± 1.38

20.43 ± 1.17

23.77* ± 1.16

AI

4.51 ± 0.58

4.31 ± 0.49

4.68 ± 0.33

3.82 ± 0.31

4.14 ± 0.35

3.43 ± 0.21

FFA (mmol/L)

0.54 ± 0.04

0.50 ± 0.03

0.49 ± 0.03

0.41 ± 0.03

0.49 ± 0.03

0.40* ± 0.02

PL (mmol/L)

1.58 ± 0.05

1.53 ± 0.05

1.61 ± 0.05

1.56 ± 0.05

1.64 ± 0.06

1.56 ± 0.04

Apo A-1 ( μg/dL)

1.82 ± 0.10

1.56 ± 0.04

1.72 ± 0.08

1.85 ± 0.12

1.66 ± 0.03

1.88 ± 0.15

Apo B ( μg/dL)

4.11 ± 0.33

4.10 ± 0.34

6.27 ± 0.63

5.55 ± 0.50

5.17 ± 0.40

4.70 ± 0.37

Apo B/Apo A-1

2.26 ± 0.63

2.62 ± 0.63

3.65 ± 0.42

3.00 ± 0.29

3.11 ± 0.23

2.50* ± 0.26

Values are mean ± S.E.; *p < 0.05, **< 0.01, ***p < 0.001 indicate significant difference before and after 10 weeks by Students' t-test; GCE, Garcinia cambogia extract; EGML, Extract of Glycine max leaves; HTR, [HDL-C/Total-C)×100]; AI, atherogenic Index, ([(Total-C)]-[HDL-C]/[HDL-C]); FFA, free fatty; PL, phospholipid; Apo A-1, Apolipoprotein A-1; Apo B, Apolipoprotein B.

Kim et al. Nutrition Journal 2011 10:94   doi:10.1186/1475-2891-10-94